1 / 63

ANTIFUNGALS LauraLe Dyner, MD Pediatric Infectious Disease Fellow October 2008

ANTIFUNGALS LauraLe Dyner, MD Pediatric Infectious Disease Fellow October 2008. Fungi. Plant-like organisms that lack chlorophyll 1 of the 5 Kingdoms More than 100,000 species 400 known to cause disease in plants, animals, and humans Cell: Chitin cell wall Cell membranes have ergosterol.

ashby
Télécharger la présentation

ANTIFUNGALS LauraLe Dyner, MD Pediatric Infectious Disease Fellow October 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ANTIFUNGALSLauraLe Dyner, MDPediatric Infectious Disease FellowOctober 2008

  2. Fungi • Plant-like organisms that lack chlorophyll • 1 of the 5 Kingdoms • More than 100,000 species • 400 known to cause disease in plants, animals, and humans • Cell: • Chitin cell wall • Cell membranes have ergosterol

  3. Fungal Cell Structure

  4. Yeasts Molds Dimorphic Candida Aspergillus Coccidioides Cryptococcus Zygomycetes Histoplasma Rhodotorula Scedosporidium Blastomycosis Cladosporidium Paracoccidiodes Ulocladium Sporothrix Fusarium Paecilomyces

  5. Yeasts • Unicellular • Although some species form pseudohyphae • Smooth in appearance • Asexual reproduction (budding/fission) is more common than sexual reproduction

  6. Molds • Multicellular • “Fuzzy” in appearance • Hyphae: determines the type of mold • Mold spores can survive harsh environments

  7. Dimorphic Fungi • Capable of growing in mold or yeast form • Differs based on environmental condition • Temperature • CO2 • Nutrients • Coccidiomycosis:

  8. Fungal Disease • Superficial/Subcutaneous • Dermatophytes • Candiadiasis • Sporotrichosis • Systemic • Exogenous • Blastomycosis, Histoplasmosis, Coccidiomycosis, Sporotrichosis • Opportunistic • Aspergillosis, Candidiasis, Cryptococcus, Zygomycosis

  9. Immunocompromised Hosts • Neonates • Oncology patients • Bone Marrow Transplant patients • Solid Organ Transplant patients • Patients with primary immunodeficiencies • Patients with HIV

  10. Invasive Fungal Infections • Neutropenic patients are particularly at risk for fungal infections • Percent of patients with neutropenia developing invasive fungal infections: • By day 20 of neutropenia, 20% of patients • By day 35 of neutropenia, 60% of patients • Most infections due to Candida and Aspergillus Wingard, CID 2004;39:S38-43

  11. Classes of Antifungals • Polyenes: Amphotericin B (1958) Abelcet (1995) Ambisome (1997) • Nucleosides: Flucytosine (1972) • Allyamines: Terbinafine (1996) • Azoles: Miconazole (1978) Ketoconazole (1981) Fluconazole (1990) Itraconazole (1992) Voriconazole (2002) Posaconzole (2006) • Echinocandins: Caspofungin (2001) Micafungin (2005) Anidulafungin (2006)

  12. Classes of Antifungals • Polyenes: Amphotericin B (1958) Abelcet (1995) Ambisome (1997) • Nucleosides: Flucytosine (1972) • Allyamines: Terbinafine (1996) • Azoles: Miconazole (1978) Ketoconazole (1981) Fluconazole (1990) Itraconazole (1992) Voriconazole (2002) Posaconzole (2006) • Echinocandins: Caspofungin (2001) Micafungin (2005) Anidulafungin (2006)

  13. Polyenes • Amphotericin B, Ambisome, Abelcet • Nystatin

  14. Polyenes • Mechanism: • Binds to ergosterol in the fungal cell membrane leakage of the intracellular cations and cell death • Selectivity is based on the difference in fungal vs. mammalian cell membrane (ergosterol vs. cholesterol) • Resistance is rare and mediated by changes in ergosterol content in fungal cell membrane

  15. Amphotericin

  16. Amphotericin: Antifungal activity • Most Candida & Aspergillus • Does not have activity against: • Candida lusitaniae & guilliermondii • Aspergillus terreus & some flavus • Fusarium • Scedosporidium

  17. Amphotericin: Toxicity • Can also bind to cholesterol • Its oxidation causes free radicals • **Nephrotoxicity • Dose-dependent • Increases with other nephrotoxic medications • Electrolyte abnormalities • Infusion reactions • Fever, rigors, headache, nausea, vomiting • Anemia • Thrombophlebitis

  18. Amphotericin: Drug Interactions • Synergistic (increasing uptake) • Rifampin • Flucytosine • Tetracyclines • Antagonistic • Imidazoles (Ketoconazole, Clotrimazole)

  19. Amphotericin Lipid Formulations • AmBisome • Abelcet • Amphotec

  20. Amphotericin Lipid Formulations • Major advantage is that they have less nephrotoxicity • Require higher doses • 3 mg/kg/day for candidiasis • 4-6 mg/kg/day for invasive fungal infections • Decreased severity and frequency of acute infusion reactions

  21. Classes of Antifungals • Polyenes: Amphotericin B (1958) Abelcet (1995) Ambisome (1997) • Nucleosides: Flucytosine (1972) • Allyamines: Terbinafine (1996) • Azoles: Miconazole (1978) Ketoconazole (1981) Fluconazole (1990) Itraconazole (1992) Voriconazole (2002) Posaconzole (2006) • Echinocandins: Caspofungin (2001) Micafungin (2005) Anidulafungin (2006)

  22. Nucleoside Analogs • Flucytosine

  23. Nucleoside Analogs • Mechanism: • DNA substrate analog that leads to incorrect DNA synthesis • Only given PO • Often used in combination with Amphotericin • Should not be used as monotherapy • Resistance develops rapidly through alteration of cytosine permease or altered metabolism

  24. Nucleoside Analogs

  25. Nucleoside Analogs: Antifungal activity • Candida & Cryptococcus • Does not have activity against: • Molds • *Well distributed in the CNS*

  26. Nucleosides: Toxicity • Bone Marrow suppression • Abdominal pain • Loose stools

  27. Classes of Antifungals • Polyenes: Amphotericin B (1958) Abelcet (1995) Ambisome (1997) • Nucleosides: Flucytosine (1972) • Allyamines: Terbinafine (1996) • Azoles: Miconazole (1978) Ketoconazole (1981) Fluconazole (1990) Itraconazole (1992) Voriconazole (2002) Posaconzole (2006) • Echinocandins: Caspofungin (2001) Micafungin (2005) Anidulafungin (2006)

  28. Allyamines • Terbinafine

  29. Allyamines • Mechanism: • Reduced ergosterol biosynthesis • Terbinafine specifically inhibits squalene epoxidase • Highly lipophilic; accumulates in skin, nails, and fatty tissue • Treats dermatophytes

  30. Terbinafine

  31. Classes of Antifungals • Polyenes: Amphotericin B (1958) Abelcet (1995) Ambisome (1997) • Nucleosides: Flucytosine (1972) • Allyamines: Terbinafine (1996) • Azoles: Miconazole (1978) Ketoconazole (1981) Fluconazole (1990) Itraconazole (1992) Voriconazole (2002) Posaconzole (2006) • Echinocandins: Caspofungin (2001) Micafungin (2005) Anidulafungin (2006)

  32. Azoles • 5-membered organic ring with either 2 or 3 nitrogen molecules • 2 = Imidazoles • 3 = Triazoles

  33. Imidazoles • Clotrimazole • Miconazole • Ketoconazole

  34. Triazoles • Fluconazole • Itraconazole • Voriconazole • Posaconazole

  35. Triazoles • Mechanism • Inhibits the fungal cytochrome P450 14-alpha dexamethylase; an enzyme that acts in ergosterol biosynthesis • Resistance • Mutations in the target enzymes • Upregulation of efflux transporters

  36. Triazoles

  37. Azole Drug Interactions

  38. Azole Drug Interactions • Rifampin • Sirolimus • Tacrolimus • Cyclosporine • Corticosteroids

  39. Fluconazole: Antifungal activity • Most Candida species, Cryptococcus, Coccidioides • Does not have activity against: • Candida krusei (intrinsically resistant) • Candida glabrata (dose-dependent resistance) • Aspergillus

  40. Fluconazole • Excellent bioavailability • Metabolized by the liver (cytochrome P450) • Cleared by the kidney • Required renal dosing • Few side effects • Can see transaminitis

  41. Itraconazole: Antifungal activity • Candida, Cryptococcus, Histoplasma, Coccidioides, Aspergillus

  42. Itraconazole • Absorption is not reliable • 55% for the solution • Less with the capsule • Metabolized by cytochrome P450 • Cleared by the kidney • Requires renal dosing

  43. Voriconazole: Antifungal activity • Candida, Aspergillus, Fusarium, Scedosporidium • Has coverage for fluconazole resistant species of Candida and Aspergillus • Does not have activity against: • Zygomycetes

  44. Voriconazole • Bioavailability > 95% • Metabolized by CYP2C19 • Requires renal dosing for the IV formulation • PO voriconazole does not require renal dosing • Side effects • Visual disturbances • Photosensitivity

  45. Voriconazole: Drug Interactions • Sirolimus levels can be dramatically increased • Not advised while on Voriconazole • May need to decrease: • Tacrolimus • Cyclosporine • Coumadin • Omeprazole

  46. Posaconazole: Antifungal activity • Similar to Voriconazole • Candida, Aspergillus, Fusarium, Scedosporidium • Includes Zygomycetes

  47. Classes of Antifungals • Polyenes: Amphotericin B (1958) Abelcet (1995) Ambisome (1997) • Nucleosides: Flucytosine (1972) • Allyamines: Terbinafine (1996) • Azoles: Miconazole (1978) Ketoconazole (1981) Fluconazole (1990) Itraconazole (1992) Voriconazole (2002) Posaconzole (2006) • Echinocandins: Caspofungin (2001) Micafungin (2005) Anidulafungin (2006)

More Related